Clinical Cancer Research Bridging the Lab and the Clinic in Cancer Medicine Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dai, S.
Right arrow Articles by Cao, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dai, S.
Right arrow Articles by Cao, X.
Clinical Cancer Research Vol. 11, 7554-7563, October 15, 2005
© 2005 American Association for Cancer Research

Cancer Therapy: Preclinical

More Efficient Induction of HLA-A*0201-Restricted and Carcinoembryonic Antigen (CEA)–Specific CTL Response by Immunization with Exosomes Prepared from Heat-Stressed CEA-Positive Tumor Cells

Shengming Dai1, Tao Wan2, Baomei Wang2, Xiangyang Zhou2, Fangming Xiu1, Taoyong Chen2, Yanfeng Wu2 and Xuetao Cao1,2

Authors' Affiliations: 1 Institute of Immunology, Zhejiang University, Hangzhou, People's Republic of China and 2 Institute of Immunology, Second Military Medical University, Shanghai, People's Republic of China

Requests for reprints: Xuetao Cao, Institute of Immunology, Zhejiang University, 353 Yanan Road, Hangzhou 310031, People's Republic of China. Fax: 86-571-8721-7329; E-mail: caoxt{at}public3.sta.net.cn.


   Abstract
Top
 Abstract
Materials and Methods
 Results
 Discussion
 References
 
Purpose: Tumor-derived exosomes are proposed as a new type of cancer vaccine. Heat shock proteins are potent Th1 adjuvant, and heat stress can induce heat shock protein and MHC-I expression in tumor cells, leading to the increased immunogenicity of tumor cells. To improve the immunogenicity of exosomes as cancer vaccine, we prepared exosomes from heat-stressed carcinoembryonic antigen (CEA)–positive tumor cells (CEA+/HS-Exo) and tested the efficacy of these exosomes in the induction of CEA-specific antitumor immunity.

Experimental Design: First, we identified the composition of CEA+/HS-Exo and observed their effects on human dendritic cell maturation. Then, we evaluated their ability to induce a CEA-specific immune response in vivo in HLA-A2.1/Kb transgenic mice and CEA-specific CTL response in vitro in HLA-A*0201+ healthy donors and HLA-A*0201+CEA+ cancer patients.

Results: CEA+/HS-Exo contained CEA and more heat shock protein 70 and MHC-I and significantly induced dendritic cell maturation. Immunization of HLA-A2.1/Kb transgenic mice with CEA+/HS-Exo was more efficient in priming a CEA-specific CTL, and the CTL showed antitumor effect when adoptively transferred to SW480-bearing nude mice. Moreover, in vitro incubation of lymphocytes from HLA-A*0201+ healthy donors and HLA-A*0201+CEA+ cancer patients with CEA+/HS-Exo-pulsed autologous dendritic cells induces HLA-A*0201-restricted and CEA-specific CTL response.

Conclusions: Our results show that CEA+/HS-Exo has superior immunogenicity than CEA+/Exo in inducing CEA-specific CTL response and suggest that exosomes derived from heat-stressed tumor cells may be used as efficient vaccine for cancer immunotherapy.

Carcinoembryonic antigen (CEA) is a heavily glycosylated oncofetal antigen that is overexpressed in human adenocarcinomas, especially in colon, pancreas, breast, and lung (1–3). The tissue expression pattern makes CEA a potential target for tumor-specific immunotherapy. Recent studies have revealed that CEA-specific CTLs can be induced after the administration of CEA protein mixed with adjuvants, altered peptide of CEA, anti-idiotype antibodies of CEA, and CEA-based recombinant poxvirus vaccines (4–9). However, as a self-protein and due to immune tolerance, CEA is poorly immunogenic; thus, more efforts should be put into exploring a successful strategy to improve the efficiency of CEA-based tumor immunotherapy.

Exosomes are membrane vesicles, with a diameter of 30 to 90 nm, derived from the fusion of small internal compartments with the plasma membrane in many types of cells, including tumor cells (10, 11). Recently, studies have suggested that exosomes can serve as a new kind of vaccine with promising therapeutic effects in cancer immunotherapy. Exosomes derived from tumor antigen peptide-pulsed dendritic cells elicit potent tumor-specific immune responses (12). Exosomes derived from tumor cells are also a source of shared tumor rejection antigens for CTL cross-priming in animal model (13). However, the antitumor activity of the pure exosomes applied are not strong and thus need to be enhanced. In combination with proper adjuvants, exosome-based cancer vaccines can enhance the host immune responses against tumors. For example, recently, it is reported that exosomes admixed with CpG oligonucleotides were efficient in prophylactic and therapeutic settings of melanoma in HLA-A2 transgenic mice (14).

Accumulating evidence has shown that hyperthermia is a promising approach in cancer therapy; its possible mechanism of antitumor immunity is attributed to the high expression of heat shock protein (HSP) 70 and MHC-I on heat-stressed tumor cells (15–18). HSP70 prepared from tumor cells or virus-infected cells can elicit potent antigen-specific CD8+ CTL response and therapeutic effects. It is an effective molecular adjuvant for the induction of a Th1 immune response. Evidence has revealed that by priming antigen-presenting cells, especially dendritic cells, HSP70 exhibits potent adjuvant functions in stimulating the host immune response (19–23) and has a potent antitumor effect in animal model (21–23). As such, clinical trials using HSP70 for tumor therapy are being carried out (24).

In this study, we investigated whether exosomes from the heat-stressed CEA+ human tumor cells (CEA+/HS-Exo) are capable of inducing CEA-specific antitumor immune response more efficiently than the exosomes conventionally prepared from the same tumor cells (CEA+/Exo). Our results show that CEA+/HS-Exo contain more HSP70 and MHC-I molecules and exhibit superior immunogenicity than CEA+/Exo. Furthermore, CEA+/HS-Exo induce a potent CEA-specific CTL response both in vitro and in vivo, suggesting that exosomes from the heat-stressed tumor cells could be potential vaccines for cancer immunotherapy.


   Materials and Methods
Top
 Abstract
 Materials and Methods
Results
 Discussion
 References
 
Materials. Peridinin chlorophyll protein–labeled anti-HLA-DR, FITC-conjugated anti-CD80, phycoerythrin (PE)–conjugated anti-CD86, PE-conjugated anti-CD40, and FITC-labeled anti-CD8 were purchased from BD Biosciences PharMingen (Chicago, IL). FITC-conjugated anti-HLA-A2 monoclonal antibody (clone BB7.2) was from Serotec Ltd. (Oxford, United Kingdom). Anti-human CEA (CE05) was from Neomarker (Fremont, CA). Anti-HSP27 (F-4), anti-HSP40 (C-20), anti-HSP60 (H-1), anti-HSP70 (K-20), anti-Hsc70 (B6), anti–intercellular adhesion molecule-1 (C-19), anti-B7.1 (N-20), anti-B7.2 (C-19), anti-transferrin receptor (K-20), and anti–lysosome-associated membrane glycoprotein-3 were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-MHC-I (HC10) was from Roswell Park Cancer Institute (Buffalo, NY). Horseradish peroxidase–coupled secondary antibodies were from Jackson ImmunoResearch (West Grove, PA). Recombinant mouse interleukin (IL)-2 and recombinant human IL-2 were commercially obtained from Sigma (St. Louis, MO). Recombinant human IL-7 and IL-10 were from Peprotech, Inc. (Rocky Hill, NJ). Micro SSp DNA Typing for confirmation of HLA-A*0201 expression was purchased from One Lambda, Inc. (CA). The protein assay kit was purchased from Bio-Rad, Inc. (Hercules, CA). The Limulus amebocyte lysate assay was from BioWhittaker (Walkersville, MD). Aldehyde/sulfate latex beads (4 µm in diameter) were from Interfacial Dynamics (Portland, OR). Chemiluminescence detection kits were from Pierce (Rockford, IL). HLA-A*0201/CAP-1-tetramersPE were from ProImmune (Oxford BioBusiness Centre, Littlemore Park, Oxford, United Kingdom). HLA-A*0201/SSp-1-tetramersPE were constructed in our laboratory. Ficoll-Paque, [3H]thymidine, and 51Cr sodium chromate were from Amersham Pharmacia Biotech (Arlington Heights, IL). Fetal bovine serum was from Hyclone (Logan, UT). Mouse and human IFN-{gamma}, human IL-12p70, and tumor necrosis factor-{alpha} ELISA kits were from R&D Systems (Minneapolis, MN). Anti-CD3 and anti-CD4 magnetic beads were from Miltenyi Biotech (Auburn, CA).

Peptides. The CEA peptide CAP-1 (YLSGANLNL) and the coronavirus SARS-CoV spike protein peptide SSp-1 (RLNEVAKNL) were synthesized at GL Biochem Ltd. (Shanghai, China) with purity of >95%.

Animals and cell lines. HLA-A2.1/Kb transgenic mice (6-8 weeks of age) were purchased from The Jackson Laboratory (Bar Harbor, ME). Four-week-old athymic nude mice were obtained from SIPPR-BK Experimental Animal Co. (Shanghai, China). The mice were housed in a pathogen-free facility for all experiments.

Human colon carcinoma cell lines LS-174T (HLA-A2+CEA+), SW480 (HLA-A2+CEA+), LoVo (HLA-A2–CEA+), human lung carcinoma cell line A549 (HLA-A2+CEA–), and human TAP-deficient T2 cell lines were obtained from the American Type Culture Collection (Manassas, VA) and maintained in culture medium according to the supplier's specifications.

Patients and healthy donors. Patients and HLA-A*0201+ healthy donors were required to give informed consent before participation in the study. Entry criteria for patients with colon cancer were as follows: histologic confirmation of CEA expression (as defined by immunohistochemical analysis), confirmation of HLA-A*0201 expression by PCR-based DNA typing, high level of CEA in serum, no chemotherapy or radiotherapy 4 weeks before the study, and no organic dysfunction of the liver and kidneys.

Exosome purification. Exosomes were purified from 48-hour supernatants of 80% confluent tumor cells cultured in medium deprived of bovine exosomes by overnight centrifugation of bovine serum at 100,000 x g (25). To prepare heat-stressed tumor cell–derived exosomes (HS-Exo), tumor cells were first cultured at 37°C for 43 hours, sequentially incubated in a 43°C water bath for 1 hour, and recovered in a 37°C incubator for 4 hours. Exosomes derived from both non-heat-stressed (Exo) and heat-stressed tumor cells were purified as described previously (26). Exosome pellets obtained after 100,000 x g centrifugation for 1 hour were washed once in a large volume of PBS and then centrifuged at 100,000 x g for 1 hour, and the pellets were resuspended in 50 to 100 µL PBS. For further purification, the exosome suspensions were layered onto a 30% to 45% (w/v) discontinuous density sucrose cushion (density 1.13-1.19 g/mL) and centrifuged at 100,000 x g for 2 hours; then, exosome interface was collected and washed with PBS. The protein concentrations of exosomes were quantified by Bradford assay. All exosomes are free of endotoxin as confirmed by Limulus amebocyte lysate assay.

Electron microscopy. The purified exosomes were fixed for 1 hour in 4% paraformaldehyde and washed once with PBS. Then, the pellets were fixed in 2.5% glutaraldehyde, loaded on Formwar/carbon–coated EM grids, postfixed in 1% glutaraldehyde, and contrasted successively in 2% methycellulose/0.4% uranyl acetate (pH 4.0). Observations were made with a Philips EM410 electron microscopy (Eindhoven, the Netherlands).

Fluorescence-activated cell sorting analysis of HLA-A2 onexosomes. Exosomes were analyzed by fluorescence-activated cell sorting (FACS) analysis as described previously with minor modification (27). Briefly, 20 µg exosomes or 20 µg FCS proteins (negative control) were incubated with 5 µL of 4-µm-diameter aldehyde/sulfate latex beads for 15 minutes at room temperature in a 20-µL final volume followed by gentle shaking for 1 hour in 1 mL PBS and then centrifuged. The pellet was blocked by incubation with 20 µL FCS for 30 minutes. Exosomes or FCS-coated beads were washed thrice in PBS and resuspended in 50 µL PBS. In parallel, heat-stressed or non-heat-stressed LS-174T cells were washed twice in PBS. Cells (105) or 20 µL coated beads were incubated for 45 minutes with FITC-conjugated anti-HLA-A2 monoclonal antibody, washed, and analyzed on a FACSCalibur (Becton Dickinson, Mountain View, CA).

Western blot analysis. The same amount of exosomes or cell lysate proteins was separated on SDS-PAGE and transferred to Bioblot-NC membranes (Costar, Nepean, Ontario, Canada). The membranes were blocked for 1 hour in TBST containing 5% nonfat milk and then incubated with primary antibodies as indicated at the supplier's recommended dilutions followed by horseradish peroxidase–coupled secondary antibodies and chemiluminescence detection.

Dendritic cell maturation. Human peripheral blood monocyte–derived dendritic cells were generated as described by us (28). On day 5, monocyte-derived dendritic cells were stimulated with 5 µg/mL exosomes or 1 µg/mL lipopolysaccharide (LPS) or PBS for 48 hours, harvested, and washed. For phenotypic analysis, dendritic cells were incubated with the indicated labeled antibodies for 45 minutes at 4°C before flow cytometry analysis. To quantify cytokine secretion, day 5 dendritic cells (5 x 105/mL) were stimulated with 5 µg/mL exosomes or 1 µg/mL LPS or PBS for 24 hours. IL-12p70 and tumor necrosis factor-{alpha} in supernatants were measured by ELISA kits (29).

Mixed lymphocyte reaction. Allogeneic T-cell response was assessed as described previously (30). On day 5, immature dendritic cells were incubated with 5 µg/mL exosomes or medium (negative control) and 1 µg/mL LPS (positive control) for 48 hours and then irradiated as stimulator cells. T cells were enriched from peripheral blood mononuclear cells of a different donor using anti-CD3 magnetic beads as responder cells and incubated with the irradiated dendritic cells at different responder/stimulator ratios as indicated. [3H]Thymidine (0.5 µCi/well) was added 72 hours later, and cells were incubated for further 18 hours. [3H]Thymidine incorporation was assayed by liquid scintillation counting.

Cytotoxicity assays. Cytotoxicity assays were done using a standard 4-hour 51Cr release assay as described (31). T2 cells are pulsed with CAP-1 or SSp-1. Peptide-pulsed T2 cells and SW480 and LoVo cells were labeled with 51Cr sodium chromate (100 µCi/106 cells) in triplicate for 90 minutes at 37°C and washed thrice as target cells. Target cells (104 per well) and effector cells were plated in a final volume of 200 µL in 96-well round-bottomed plate. After 4 hours, each supernatant (100 µL) was harvested and then measured for the release of 51Cr (gamma counter). The specific cytotoxicity was determined according to the following formula: [(counts/min of experimental 51Cr release – counts/min of the spontaneous 51Cr release) / (counts/min of the maximal 51Cr release – counts/min of the spontaneous 51Cr release)] x 100%. The spontaneous 51Cr release was determined by incubating the target cells alone in the absence of effectors, and the maximal 51Cr release was obtained by incubating the targets with 5% Triton X-100. The spontaneous release was always <15% of maximum release.

CTL induction in HLA-A2.1/Kb transgenic mice. HLA-A2.1/Kb transgenic mice were s.c. immunized with 5 µg exosomes on the posterior right of the back weekly for three times. The control groups were injected with A549 (HLA2+CEA–)–derived exosomes or PBS. For the dosage escalation experiments, 2.5, 5, 10, and 15 µg exosomes were used for each vaccination per mouse. The mice were sacrificed 7 days after the third immunization, and murine bone marrow–derived dendritic cells were prepared as described previously (32). On day 7, dendritic cells were harvested and pulsed with 10 µg/mL peptides. Splenocytes (2 x 106) from immunized transgenic mice were restimulated with CAP-1-loaded irradiated syngeneic dendritic cells (2 x 105) for 6 days. The cytotoxicity was assayed as described above.

For the IFN-{gamma} release assay, splenocytes (2 x 105) were restimulated with 10 µg/mL CAP-1, SSp-1, or 5 µg/mL concanavalin A for 72 hours in 96-well round-bottomed microculture plates, the supernatants were collected for IFN-{gamma} measurement. For the tetramer staining assay, the lymphocytes from injected side draining lymph node of immunized transgenic mice were tested according to the manufacturer's protocol.

Adoptive transfer. Four-week-old athymic nude mice were inoculated s.c. on the right side, behind the anterior forelimb with SW480 tumor cells (1 x 107) in 0.2 mL serum-free culture medium, as described previously (33). On day 7, when tumors reached 4 to 5 mm in diameter, the mice were randomly divided into several groups (n = 5). On days 7 and 14, splenocytes (2 x 108) from exosome-immunized transgenic mice were injected i.p. in SW480-bearing nude mice. From days 7 to 21, recombinant IL-2 (10,000 units) was given i.p. Control mice received recombinant IL-2 alone or PBS alone. Tumor growth was measured every other day in two dimensions using a digital caliper. Tumor volume was calculated as (length x width2) / 2 and presented as mean ± SD (mm3). The survival rate was observed.

In vitro CTL generation from HLA-A*0201+ healthy donors and HLA-A*0201+CEA+ cancer patients. CTL were generated as described previously by us (31). Briefly, autologous dendritic cells (2 x 105 per well) were pulsed with 10 µg exosomes in a 24-well plate for 2 hours in 200 µL culture medium. Lymphocytes were then added at a ratio of 10 lymphocytes to 1 dendritic cell in a final volume of 2 mL/well in the presence of 10 ng/mL IL-7. One day later, recombinant human IL-10 was supplemented to the culture to a final concentration of 10 ng/mL. After 7 days, lymphocytes were restimulated with exosome-pulsed autologous dendritic cells in medium containing IL-7 (10 ng/mL) and IL-10 (10 ng/mL) and then supplemented with 20 units/mL recombinant hIL-2 a day later. Individual wells were restimulated separately every 7 days up to four cycles with dendritic cells pulsed with exosomes. On day 28, stimulated lymphocytes were harvested and tested by IFN-{gamma} release assay, cytotoxicity capacity, and tetramer staining. For IFN-{gamma} release assay and cytotoxicity assays, CD8+ T lymphocytes were purified by CD4+ cell–negative depletion using human CD4 microbeads. IFN-{gamma} release assay was done as described by Kim et al. (34), with minor modification. Peptide-pulsed T2 cells were used as stimulator cells. Effector cells (5 x 104) and stimulator cells (1 x 104) were cocultured in 96-well microplates. After 24 hours of incubation, supernatants were collected and measured for IFN-{gamma} production by ELISA.

Statistical analysis. The differences of the tumor diameters were compared using the Mann-Whitney U test. The differences of the survival were done using Kaplan-Meier test. All other statistical analyses were done using a two-tailed t test. Ps ≤ 0.05 were considered significant.


   Results
Top
 Abstract
 Materials and Methods
 Results
Discussion
 References
 
Heat stress enriches heat shock protein 70 and MHC-I proteins in exosomes. The pellets obtained from ultracentrifugations of culture supernatants of LS-174T cell lines were first analyzed morphologically by electron microscopy. The pellets consisted of 30- to 90-nm-diameter bilayer membrane vesicles (Fig. 1A) and showed typical exosome morphology described by others (10–14). The components in Exo and HS-Exo were analyzed by Western blot and by FACS analysis of exosome-coated beads. The native tumor antigen CEA was detected in all exosomes derived from CEA+ tumor cell lines (LS-174T and LoVo cell lines) but not in exosomes derived from CEA– tumor cell line (A549 cell line), and it was not altered after heat stress (Fig. 1B). Inducible and constitutive HSPs, including HSP70 and Hsc70 but not HSP60, HSP40, and HSP27, were selectively detected in Exo and HS-Exo, but HSP70 was greatly enriched in HS-Exo (Fig. 1B). High levels of MHC-I molecules were found in Exo and accumulated in HS-Exo (Fig. 1B), consistent with previous reports showing that exosomes derived from dendritic cells, B cells, or tumor cells bear MHC-I (12, 13, 35, 36). Moreover, transferrin receptor and lysosome-associated membrane glycoprotein-3 (a tetraspanin that is a specific marker of late endosomes) were detectable in both Exo and HS-Exo, suggesting that exosomes were originated from a late endosomal compartment (Fig. 1B). However, adhesion molecules (intercellular adhesion molecule-1) and costimulatory molecules (B7.1 and B7.2) are undetectable in our study (Fig. 1B).



View larger version (48K):
[in this window]
[in a new window]
  		Fig. 1. Electron microscopy and protein patterns of exosomes. A, electron microscopy of exosomes derived from LS-174T cells. The size of those exosomes is 30 to 90 nm in diameter. Arrows, lipid bilayer membranes of exosomes. Bar, 100 nm. B, Western blot of protein components of exosomes. Tumor cell lysates or exosomal proteins were analyzed by Western blot using indicated antibodies. C, FACS analysis of bead-coated exosomes. The same amounts of FCS proteins (negative control) or Exo (coarse line) or HS-Exo (broken line) were coated on beads, stained with FITC-labeled anti-HLA-A2 monoclonal antibody, washed, and analyzed on a FACSCalibur. Negative FCS controls are indicated by fine lines. D, FACS analysis of HLA-A2 expression on LS-174T cells. LS-174T cells (coarse line) and heat-stressed LS-174T cells (broken line) were incubated with FITC-labeled anti-HLA-A2 and analyzed by FACS. Negative isotype control is indicated by a fine line.

 
To elucidate whether exosomes from HLA-A2+ LS-174T cells (LS-Exo or LS-HS-Exo) bear HLA-A2 and whether the expression of HLA-A2 was different after tumor cells were subjected to heat stress, exosome-coated beads were analyzed by FACS. Both LS-Exo and LS-HS-Exo carried HLA-A2, but the mean fluorescence value increased in LS-HS-Exo (Fig. 1C), in line with the data that heat stress enhanced the surface expression of HLA-A2 in LS-174T cells (Fig. 1D). As a negative control, HLA-A2 molecules were not found in LoVo-derived exosomes (LoVo-Exo and LoVo-HS-Exo; Fig. 1C). These results suggest that heat stress causes the accumulation of MHC-I and HLA-A2 in HS-Exo of HLA-A2+ tumor cells.

Therefore, up-regulating HSP70/MHC-I and causing HSP70/MHC-I enrichment in exosomes through heat stress possibly offer great potential as a new approach to enhance immunogenicity.

Exosomes from heat-stressed tumor cells induce dendritic cell maturation more efficiently. Based on the report that mast cell–derived exosomes induce dendritic cell maturation (29), we analyzed the phenotypic and functional alterations of dendritic cells on exposure to different types of exosomes. The results showed that LS-HS-Exo strongly up-regulated the expression of HLA-DR, CD86, and CD40 in dendritic cells compared with LS-Exo (Fig. 2A). IL-12p70 and tumor necrosis factor-{alpha} production in the culture supernatants was greatly enhanced by LS-HS-Exo, to the extent comparable with that of LPS but significantly higher than that of LS-Exo (Fig. 2B and C). In mixed lymphocyte reaction, LS-HS-Exo-, LS-Exo-, and LPS-treated dendritic cells all induced T-cell proliferation. However, dendritic cells loaded with LS-HS-Exo were more effective in stimulating a proliferative response than that with LS-Exo (Fig. 2D). These data show that LS-HS-Exo are more effective in inducing phenotypic and functional maturation of dendritic cells than LS-Exo, suggesting that the function of enriched HSP70 in HS-Exo may be enrolled in induction of dendritic cell maturation.




View larger version (59K):
[in this window]
[in a new window]
  		Fig. 2. Phenotypic and functional maturation of dendritic cells induced by LS-HS-Exo. A, human dendritic cells (5 x 105/mL) were incubated with 5 µg/mL LS-Exo or LS-HS-Exo on day 5. After 48 hours of incubation, dendritic cells were collected and stained with monoclonal antibodies specific to HLA-DR, CD80, CD86, and CD40. Positive controls (1 µg/mL LPS) and negative controls (PBS) for dendritic cell maturation were used. Fine line, isotype control; coarse line, PBS treatment; broken line, exosomes or the LPS treatment. B and C, supernatants were tested by ELISA for contents of IL-12p70 and tumor necrosis factor-{alpha} after 24 hours of incubation as described in (A). *, P < 0.05, LS-HS-Exo versus LS-Exo. D, mixed lymphocyte reaction assay. *, P < 0.01, LS-HS-Exo versus LS-Exo.

 
More efficient induction of carcinoembryonic antigen–specific CTL response in HLA-A2.1/Kb transgenic mice by CEA+/HS-Exo. To assess the capacity of tumor cell–derived exosomes to induce an effective T-lymphocyte-mediated immune response in vivo, we immunized HLA-A2.1/Kb transgenic mice with 2.5, 5, 10, or 15 µg exosomes. Cytotoxicity assay showed that LS-HS-Exo or LoVo-HS-Exo (5 µg) was efficient in the generation of substantial immunity in HLA-A2.1/Kb transgenic mice, whereas the same amounts of LS-Exo or LoVo-Exo were insufficient (Fig. 3A). CEA-specific HLA-A2.1-restrcited CTL could be more readily induced in HLA-A2.1 transgenic mice by immunization with 5 µg LS-HS-Exo or LoVo-HS-Exo than by immunization with LS-Exo or LoVo-Exo as judged by the lysis of SW480 (HLA-A2+CEA+) and CAP-1 pulsed T2 cells (data not shown) but not LoVo (HLA-A2–CEA–; Fig. 3A), SSp-1 pulsed T2 cells and native T2 cells (data not shown) and by an IFN-{gamma} release (Fig. 3B). CEA-A549-derived exosomes (A549-Exo or A549-HS-Exo) could not induce CEA-specific CTL response (Fig. 3A and B).



View larger version (25K):
[in this window]
[in a new window]
  		Fig. 3. Immunization with CEA+/HS-Exo induces a CEA-specific CTL activity in HLA-A2.1/Kb transgenic mice more efficiently. A, HLA-A2.1/Kb transgenic mice (n = 3 per group) were immunized with increasing amounts of exosomes as indicated. For the murine cytotoxicity assay, splenocytes (2 x 106) were restimulated with CAP-1-pulsed dendritic cells (2 x 105) for 6 days in complete medium supplemented with 50 units/mL recombinant IL-2 in six-well plates; then, cytotoxicity was tested using a 51Cr standard cytotoxicity assay. SW480 and LoVo were used as target cells (E:T = 50:1). *, P < 0.01, LS-HS-Exo versus LS-Exo or LoVo-HS-Exo versus LoVo-Exo. B, splenocytes (2 x 105) from transgenic mice immunized with 5 µg exosomes or control mice (PBS injected) were cultured in 96-well round-bottomed microculture plates. Cells were restimulated with CAP-1, SSp-1, or concanavalin A (ConA). Cell culture supernatants were removed at 72 hours to determine IFN-{gamma} release. *, P < 0.05, LS-HS-Exo versus LS-Exo; *, P < 0.05, LoVo-HS-Exo versus LoVo-Exo. C, FACS analysis of HLA-A*0201/CAP-1-tetramer-binding lymphocytes. Lymphocytes from draining lymph node were stained with HLA-A*0201/CAP-1-tetramersPE or HLA-A*0201/SSp-1-tetramersPE and anti-CD8FITC antibodies. Quadrants were set based on negative controls. The numbers of tetramer+ cells are expressed (top right quadrants) as a percentage of the CD8+ lymphocyte population. SSp-1 tetramer binding to lymphocytes from transgenic mice immunized with 5 µg LoVo-HS-Exo (top left) or LS-HS-Exo (bottom left). CAP-1 tetramer binding to the lymphocytes from transgenic mice immunized with 5 µg LoVo-HS-Exo (top right) or LS-HS-Exo (bottom right).

 
CAP-1-specific CD8+ T cells from the draining lymph node of injection sites in LoVo-HS-Exo- or LS-HS-Exo-injected transgenic mice made up 2.73% and 4.21% of the total number of CD8+ T cells by HLA-A*0201/CAP-1-tetramer staining, respectively, but tetramers of control epitope HLA-A*0201/SSp-1-tetramer were not detected (0.03% and 0.02%, respectively; Fig. 3C).

The results suggest that CEA+/HS-Exo (either LS-HS-Exo or LoVo-HS-Exo) are effective immunogen and possess a high efficiency of antigen transfer to lead to the induction of CEA-specific CTL response.

Adoptive transfer of splenocytes from CEA+/HS-Exoimmunized HLA-A2.1/Kb transgenic mice to SW480-bearing nude mice induced antitumor immunity more efficiently. To observe the antitumor effects of splenocytes from CEA+/HS-Exo-immunized HLA-A2/Kb transgenic mice, we further investigated whether those cells could delay or abolish the outgrowth of HLA-A2+CEA+ SW480 tumor cells in nude mice after the adoptive splenocyte transfer. As shown in Fig. 4A and B, the adoptive transfer of bulk splenocytes from 5 µg LS-HS-Exo- or LoVo-HS-Exo-immunized transgenic mice, combined with IL-2 administration, markedly inhibited the growth of SW480 tumor in nude mice and improved the survival rate of these mice compared with the splenocyte-transferred mice groups marked as "LS-Exo" and "LoVo-Exo." No effect was observed following the injection of bulk splenocytes from transgenic mice immunized with A549-derived exosomes (heat stressed or not) and injection of PBS or IL-2.



View larger version (29K):
[in this window]
[in a new window]
  		Fig. 4. Antitumor effect of adoptive transferred splenocytes from transgenic mice immunized with exosomes. Athymic nude mice bearing SW480 were divided into eight treatment groups: group 1 (n = 5; {lozenge}) received i.p. splenocytes from transgenic mice immunized with 5 µg LS-HS-Exo; group 2 (n = 5; {square}) received i.p. splenocytes from transgenic mice immunized with 5 µg LoVo-HS-Exo; group 3 (n = 5; {blacktriangleup}) received i.p. splenocytes from transgenic mice immunized with 5 µg A549-HS-Exo; group 4 (n = 5; {triangleup}) received i.p. splenocytes from transgenic mice immunized with 5 µg LS-Exo; group 5 (n = 5; {blacklozenge}) received i.p. splenocytes from transgenic mice immunized with LoVo-Exo; group 6 (n = 5; {blacksquare}) received i.p. splenocytes from transgenic mice immunized with A549-Exo; group 7 (n = 5;{05-0810fx01l}) received i.p. only recombinant IL-2; group 8 (n = 5; x) received i.p. only PBS. Recombinant IL-2 (10,000 units/animal) was given by the i.p. route from days 7 to 21 after the transfer of splenocytes, except for group 8. A, assay of SW480 tumor growth after splenocytes transfer. Arrows, two administrations of splenocytes. Points, mean; bars, SD. *, P < 0.05, LS-HS-Exo versus LS-Exo or LoVo-HS-Exo versus LoVo-Exo. B, survival of SW480 tumor-bearing nude mice after splenocytes transfer. *, P < 0.05, LS-HS-Exo versus LS-Exo or LoVo-HS-Exo versus LoVo-Exo. Experiments were conducted as described in Materials and Methods.

 
These results indicate substantially that the HLA-A2.1/Kb transgenic mice can be primed in vivo with low dosage of CEA+/HS-Exo leading to the generation of CEA-specific HLA-A2.1/Kb-restricted CTL response and that the splenocytes from CEA+/HS-Exo-immunized HLA-A2/Kb transgenic mice may significantly mediate the inhibition of tumor outgrowth and survival prolongation in adoptive transfer nude mice model.

Human CTL induction by CEA+/HS-Exo-pulsed dendritic cells. Because CEA+/HS-Exo show more efficiency to induce CEA-specific CTL response in HLA-A2.1/Kb transgenic mice and these CTLs inhibit the growth of SW480 tumor in nude mice, we further investigated whether CEA+/HS-Exo-pulsed dendritic cells could induce CEA-specific CTL in HLA-A*0201+ healthy donors and especially in CEA self-tolerance cancer patients in vitro. We found that incubation of lymphocytes from HLA-A*0201+ healthy donors and HLA-A*0201+CEA+ patients with autologous dendritic cells pulsed with LS-HS-Exo or LoVo-HS-Exo did induce a HLA-A0201-restricted and CEA-specific CTL response but not with A549-HS-Exo. CEA-specific CTLs were generated in three of six HLA-A*0201+ healthy donors (Fig. 5A) and three of five HLA-A*0201+ CEA+ colon cancer patients (Fig. 5C) as judged by the lysis of SW480 cells but not LoVo cells. LS-174T-derived lysates (heat stressed or not) could not induce CEA-specific CTL production even at high dosages (data not shown).




View larger version (60K):
[in this window]
[in a new window]
  		Fig. 5. In vitro induction of human CEA-specific CTL by dendritic cells pulsed with CEA+/HS-Exo. A and B, a representative result from healthy donors; CEA-specific CTLs were generated from the peripheral blood mononuclear cells of three of six HLA-A*0201+ healthy donors through four sequential cycles of stimulation with indicated exosome-pulsed dendritic cells. Resulting CTLs were measured for CEA-specific lysis (A; *, P < 0.01, LS-HS-Exo or LoVo-HS-Exo versus A549-HS-Exo, respectively) and IFN-{gamma} production (B; *, P < 0.01, the corresponding T2/CAP-1 versus the corresponding T2/SSp-1 or native T2, respectively) using a standard 4-hour 51Cr release assay and an ELISA assay, respectively. T2 cells were pulsed with CAP-1 (T2/CAP-1) or irrelevant peptide SSp-1 (T2/SSp-1) and then used as stimulators in an IFN-{gamma} release assay. C and D, a representative result from cancer patients; CEA-specific CTLs were generated from the peripheral blood mononuclear cells of three of five HLA-A*0201+CEA+ cancer patients through four cycles of stimulation with dendritic cells pulsed with LS-HS-Exo. Resulting CTLs were tested as described above. C, CEA-specific lysis using SW480 and LoVo cells as targets. *, P < 0.01, SW480 versus LoVo. D, IFN-{gamma} release. *, P < 0.01, T2/CAP-1 versus T2/SSp-1 or native T2, respectively. E, FACS analysis of HLA-A*0201/CAP-1-tetramer-binding lymphocytes. After four rounds of in vitro stimulation, lymphocytes stimulated from a healthy individual (top) and a cancer patient (bottom) were costained with HLA-A*0201/CAP-1-tetramersPE or HLA-A*0201/SSp-1-tetramerPE and anti-CD8FITC monoclonal antibodies. Quadrants were set based on negative controls. Results are expressed as percentage of tetramer+ cells (top right quadrants) to total CD8+ lymphocytes. Top left and bottom left, binding of SSp-1 tetramer to the lymphocytes; top right and bottom right, binding of CAP-1 tetramer to lymphocytes.

 
Because CTLs are known to produce IFN-{gamma} in an antigen-specific manner, which has been regarded as a reliable indicator for a Th1 response, we measured this cytokine in the culture medium of CTL from healthy donors (Fig. 5B) and cancer patients (Fig. 5D) after T2/CAP-1 restimulation. We found that the in vitro–generated CTL induced by CEA+/HS-Exo produced a significant level of IFN-{gamma} after T2/CAP-1 stimulation, in contrast to that stimulated with T2/SSp-1 or native T2. We further examined the specificity of CTL by using peptide and MHC tetramer technology. Although CAP-1-tetramer+ lymphocytes are generally not detectable in peripheral blood mononuclear cells before restimulation, CAP-1-tetramer+ CD8+ T cells could be detected in CTL of both healthy donors and patients after four cycles of in vitro restimulation (Fig. 5E; Table 1).


View this table:
[in this window]
[in a new window]
  		Table 1. CTL induction in vitro in HLA-A*0201+ healthy individuals and HLA-A*0201+CEA+ cancer patients

 
These results showed that CEA+/HS-Exo were capable of eliciting CEA-specific CTL in a HLA-A*0201-restricted fashion in HLA-A*0201+ healthy donors and CEA+ cancer patients in vitro, suggesting that tolerance to CEA in cancer patients can be broken by CEA+/HS-Exo.


   Discussion
Top
 Abstract
 Materials and Methods
 Results
 Discussion
References
 
Although tumor immunotherapy is a promising treatment for the elimination of cancer cells, many technical challenges hinder its effective use clinically. For example, tumor antigens are often poor immunogen. Tumor cells frequently escape immune response by evolving into variants. CEA is a tumor-associated antigen with weak immunogenicity. However, CEA seems to be an attractive target for immunotherapy as it is overexpressed in ~50% of all human cancers. Exosomes as potential therapeutic agents for cancers have attracted much attention from oncologists (10, 11). However, the efficacy of conventionally prepared exosomes in antitumor induction remains to be improved. In this investigation, we have used a new method to prepare a type of exosomes from heat-stressed CEA+ tumor cells (CEA+/HS-Exo) and analyzed their structure and function. We show that both CEA+/HS-Exo and CEA+/Exo contain CEA, HSP70, Hsc70, and MHC-I, but the former seem to have higher amount of HSP70 and MHC-I molecules than the latter. Correlating with this discovery, CEA+/HS-Exo also exhibit stronger immunogenicity than CEA+/Exo both in vitro and in vivo.

HSPs are chaperones, which assist in the folding and the translocation of new synthesized proteins. Both inducible HSP70 and constitutive Hsc70 are HSP70 family members. HSP70 has immunotherapeutic potential as an adjuvant, HSP70-chaperoned antigenic peptides can be taken by antigen-presenting cells through a receptor-mediated manner to not only help the antigenic peptide presentation on MHC-I but also promote the function of antigen-presenting cells, especially dendritic cells, to generate antigen peptide-specific CD8+ T cells (22, 37–39). Besides, HSP70 can facilitate the loading of MHC-I molecules with peptides (38, 40), and Hsc70 can facilitate MHC-II antigen processing and presentation (40, 41). Therefore, enriched HSPs in exosomes may play important roles in antigen processing and presentation. This postulation might be true because we found that the immunostimulatory capacity of CEA+/HS-Exo to dendritic cells was more potent than non-heat-stressed exosomes (CEA+/Exo).

We have further assessed the antitumor immunity elicited by exosomes derived from the heat-stressed human tumor cells. On immunization with CEA+/HS-Exo (LS-HS-Exo or LoVo-HS-Exo), HLA-A2.1/Kb transgenic mice developed a strong HLA-A2.1/Kb-restricted CTL response specific for CAP-1. It is notable that the adoptive transfer of CEA-specific CTL from HLA-A2.1/Kb transgenic mice immunized by CEA+/HS-Exo results in effective inhibition of tumor growth and prolonged survival among tumor-bearing nude mice. In addition, CEA+/HS-Exo-pulsed autologous dendritic cells elicit a potent HLA-A*0201-restricted and CEA-specific CTL activity in lymphocytes from HLA-A*0201+ healthy donors or CEA+ patients. The results suggest that tolerance to CEA in cancer patients may be possibly overcome by CEA+/HS-Exo immunization.

There are so many reports showing that tumor-derived exosomes are immunogenic (10, 11, 13, 29, 35); however, there are other reports indicating that tumor-derived exosomes contain immunosuppressive molecules, such as latent membrane protein-1, NKG2D ligand, Fas ligand, and HLA-G, and have been proposed to be immunosuppressive, representing one of mechanisms of tumor evasion from the immune surveillance (42–47). This discrepancy may be due to differences in the types of exosomes produced. Therefore, identification of in-depth proteomic contents of different tumor-derived exosomes or incorporating immunologic molecules into exosomes by some strategies is a crucial aspect for aiding the understanding of their biological functions and especially targeting for use in future therapy of cancer.

In conclusion, the work described here, for the first time, has created a new way to prepare HSP70/CEA/MHC-I–enriched exosomes, and the enhanced expression of HSP70 and MHC-I in exosomes may be beneficial to promote immunogenicity of this tumor-derived membrane vesicles, especially without genetic modification or incorporation of potentially toxic adjuvants. HSP70/CEA/MHC-I–enriched exosomes released by heat-stressed tumor cells may indirectly explain the enhanced antitumor immunity by hyperthermia. Most importantly, HSP70/CEA/MHC-I–enriched exosomes are easy to obtain from CEA+ tumor cell lines and do not have limitations requiring surgical tissues. Therefore, we provide a novel strategy to improve the efficacy of exosome-based tumor vaccines, and this approach is simple and applicable for the future clinical trails of CEA+ cancer patients.


   Acknowledgments
 
We thank Dr. Guisheng Li for obtaining the blood samples of cancer patients, Prof. You-Wen He (Duke University) for critical reading of this article, and Jun Li, Linhong Sun, and Xiaohui Huang.


   Footnotes
 
Grant support: National Key Basic Research Program of China grant 2001CB510002, National Natural Science Foundation of China grants 30121002 and 30490240, National High Technology Research and Development Program of China grants 2002AA2Z3307 and 2004AA2Z3C40, and Program for New Century Excellent Talents in University grant NCET-04-0998.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 4/12/05; revised 7/14/05; accepted 7/20/05.


   References
Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 

  1. Thompson J, Zimmerman W. The carcinoembryonic antigen gene family: structure, expression and evolution. Tumour Biol 1988;9:63–83.[Medline]
  2. Gold P, Freedman SO. Demonstration of tumour-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965;121:439–62.[Abstract]
  3. Thompson JA, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Lab Clin Anal 1991;5:344–66.
  4. McAneny D, Ryan CA, Beazley RM, Kaufman HL. Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann Surg Oncol 1996;3:495–500.[Abstract]
  5. Samanci A, Yi Q, Fagerberg J, et al. Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen. Cancer Immunol Immunother 1998;47:131–47.[CrossRef][Medline]
  6. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in cancer patients of a diversified prime and boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000;18:3964–73.[Abstract/Free Full Text]
  7. von Mehren M, Arlen P, Tsang KY, et al. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res 2000;6:2219–28.[Abstract/Free Full Text]
  8. Tsang KY, Zhu MZ, Nieroda CA, et al. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen. Clin Cancer Res 1997;3:2439–49.[Abstract/Free Full Text]
  9. Zhu MZ, Marshall J, Cole D, Schlom J, Tsang KY. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. Clin Cancer Res 2000;6:24–33.[Abstract/Free Full Text]
  10. Chaput N, Taieb J, Schartz NE, Andre F, Angevin E, Zitvogel L. Exosome-based immunotherapy. Cancer Immunol Immunother 2004;53:234–9.[CrossRef][Medline]
  11. Chaput N, Schartz NE, Andre F, Zitvogel L. Exosomes for immunotherapy of cancer. Adv Exp Med Biol 2003;532:215–21.[Medline]
  12. Zitvogel L, Regnault A, Lozier A, et al. Eradication of established murine tumours using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998;4:594–600.[CrossRef][Medline]
  13. Wolfers J, Lozier A, Raposo G, et al. Tumour-derived exosomes are a source of shared tumour rejection antigens for CTL cross-priming. Nat Med 2001;7:297–303.[CrossRef][Medline]
  14. Chaput N, Schartz NEC, Andre F, et al. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumour rejection. J Immunol 2004;172:2137–46.[Abstract/Free Full Text]
  15. Ito A, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T. Augmentation of MHC class I antigen presentation via heat shock protein expression by hyperthermia. Cancer Immunol Immunother 2001;50:515–22.[CrossRef][Medline]
  16. Moroz P, Jones SK, Gray BN. Magnetically mediated hyperthermia: current status and future directions. Int J Hyperthermia 2002;18:267–84.[Medline]
  17. Van der Zee J. Heating the patient: a promising approach? Ann Oncol 2002;13:1173–84.[Abstract/Free Full Text]
  18. Ito A, Shinkai M, Honda H, et al. Heat shock protein 70 expression induces antitumour immunity during intracellular hyperthermia using magnetite nanoparticles. Cancer Immunol Immunother 2003;52:80–8.[Medline]
  19. Ishii T, Udono H, Yamano T, et al. Isolation of MHC class I-restricted tumour antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96. J Immunol 1999;162:1303–9.[Abstract/Free Full Text]
  20. Moroi Y, Mayhew M, Trcka J, et al. Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70. Proc Natl Acad Sci U S A 2000;97:3485–90.[Abstract/Free Full Text]
  21. Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity 1998;8:657–65.[CrossRef][Medline]
  22. Udono H, Srivastava PK. Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med 1993;178:1391–6.[Abstract/Free Full Text]
  23. Castelli C, Ciupitu AMT, Rini F, et al. Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res 2001;61:222–7.[Abstract/Free Full Text]
  24. Goldman B. Combinations of targeted therapies take aim at multiple pathways. J Natl Cancer Inst 2003;95:1656–7.[Free Full Text]
  25. Théry C, Regnault A, Garin J, et al. Molecular characterization of dendritic cell-derived exosomes: selective accumulation of the heat shock protein hsc73. J Cell Biol 1999;147:599–610.[Abstract/Free Full Text]
  26. Raposo G, Nijman HW, Stoorvogel W, et al. B lymphocytes secrete antigen-presenting vesicles. J Exp Med 1996;183:1–12.[Free Full Text]
  27. Théry C, Boussac M, Véron P, et al. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol 2001;166:7309–18.[Abstract/Free Full Text]
  28. Liu SX, Yu YZ, Zhang MH, Wang WY, Cao XT. The involvement of TNF-{alpha}-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-ß-stimulated human dendritic cells to tumour cells. J Immunol 2001;166:5407–15.[Abstract/Free Full Text]
  29. Skokos D, Botros HG, Demeure C, et al. Mast cell-derived exosomes induce phenotypic and functional maturation of dendritic cells and elicit specific immune responses in vivo. J Immunol 2003;170:3037–45.[Abstract/Free Full Text]
  30. Wan T, Zhou XY, Chen GY, et al. Novel heat shock protein Hsp70L1 activates dendritic cells and acts as a Th1 polarizing adjuvant. Blood 2004;103:1747–54.[Abstract/Free Full Text]
  31. Wang BM, Chen HB, Jiang XD, et al. Identification of an HLA-A*0201-restricted CD8+ T-cell epitope SSp-1 of SARS-CoV spike protein. Blood 2004;104:200–6.[Abstract/Free Full Text]
  32. Cao XT, Zhang WP, He L, et al. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific anti-tumour immunity. J Immunol 1998;161:6238–44.[Abstract/Free Full Text]
  33. Whitacre CM, Feyes DK, Satoh T, et al. Photodynamic therapy with the phthalocyanine photosensitizer Pc 4 of SW480 human colon cancer xenografts in athymic mice. Clin Cancer Res 2000;6:2021–7.[Abstract/Free Full Text]
  34. Kim CH, Todoroki T, Matsumura M, Ohno T. Eligibility of antigenic-peptide-pre-loaded and fixed adhesive peripheral blood cells for induction of cytotoxic T lymphocytes from cancer patients with elevated serum levels of carcinoembryonic antigen. J Cancer Res Clin Oncol 2000;126:383–90.[CrossRef][Medline]
  35. Andre F, Schartz NEC, Movassagh M, et al. Malignant effusion and immunogenic tumour-derived exosomes. Lancet 2002;360:295–305.[CrossRef][Medline]
  36. Clayton A, Court J, Navabi H, et al. Analysis of antigen presenting cell derived exosomes, based on immunomagnetic isolation and flow cytometry. J Immunol Methods 2001;247:163–74.[CrossRef][Medline]
  37. Ciupitu AM, Petersson M, Kono K, Charo J, Kiessling R. Immunization with heat shock protein 70 from methylcholanthrene induced sarcomas induces tumour protection correlating with in vitro T cell responses. Cancer Immunol Immunother 2002;51:163–70.[Medline]
  38. Breloer M, Marti T, Fleischer B, von Bonin A. Isolation of processed, H-2Kb-binding ovalbumin-derived peptides associated with the shock proteins HSP70 and gp96. Eur J Immunol 1998;28:1016–21.[CrossRef][Medline]
  39. Srivastava PK, Udono H, Blachere NE, Li Z. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 1994;39:93–8.[Medline]
  40. Vanbuskirk A, Crump BL, Margoliash E, Pierce SK. A peptide binding protein having a role in antigen presentation is a member of the HSP70 heat shock family. J Exp Med 1989;170:1799–809.[Abstract/Free Full Text]
  41. Cristau B, Schafer PH, Pierce SK. Heat shock enhances antigen processing and accelerates the formation of compact class II {alpha}ß dimers. J Immunol 1994;152:1546–56.[Abstract]
  42. Whiteside TL. Tumour-derived exosomes or microvesicles: another mechanism of tumour escape from the host immune system? Br J Cancer 2005;92:209–11.[CrossRef][Medline]
  43. Xiu FM, Cao XT. Exosomes in the immune response and tolerance. J Microbiol Immunol 2004;2:231–6.
  44. Dukers DF, Meij P, Vervoort MB, et al. Direct immunosuppressive effects of EBV-encoded latent membrane protein 1. J Immunol 2000;165:663–70.[Abstract/Free Full Text]
  45. Flanagan J, Middeldorp J, Sculley T. Localization of the Epstein-Barr virus protein LMP 1 to exosomes. J Gen Virol 2003;84:1871–9.[Abstract/Free Full Text]
  46. Clayton A, Tabi Z. Exosomes and the MICA-NKG2D system in cancer. Blood Cells Mol Dis 2005;34:206–13.[CrossRef][Medline]
  47. Riteau B, Faure F, Menier C, et al. Exosomes bearing HLA-G are released by melanoma cells. Hum Immunol 2003;64:1064–72.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
A. Clayton, J. P. Mitchell, J. Court, S. Linnane, M. D. Mason, and Z. Tabi
Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression
J. Immunol., June 1, 2008; 180(11): 7249 - 7258.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Koido, E. Hara, S. Homma, M. Mitsunaga, A. Takahara, E. Nagasaki, H. Kawahara, M. Watanabe, Y. Toyama, S. Yanagisawa, et al.
Synergistic Induction of Antigen-Specific CTL by Fusions of TLR-Stimulated Dendritic Cells and Heat-Stressed Tumor Cells
J. Immunol., October 1, 2007; 179(7): 4874 - 4883.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Clayton, J. P. Mitchell, J. Court, M. D. Mason, and Z. Tabi
Human Tumor-Derived Exosomes Selectively Impair Lymphocyte Responses to Interleukin-2
Cancer Res., August 1, 2007; 67(15): 7458 - 7466.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. R. Rheingold, M. D. Hogarty, S. M. Blaney, J. A. Zwiebel, C. Sauk-Schubert, R. Chandula, M. D. Krailo, and P. C. Adamson
Phase I Trial of G3139, a bcl-2 Antisense Oligonucleotide, Combined With Doxorubicin and Cyclophosphamide in Children With Relapsed Solid Tumors: A Children's Oncology Group Study
J. Clin. Oncol., April 20, 2007; 25(12): 1512 - 1518.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Saha, S. K. Chatterjee, K. A. Foon, E. Celis, and M. Bhattacharya-Chatterjee
Therapy of Established Tumors in a Novel Murine Model Transgenic for Human Carcinoembryonic Antigen and HLA-A2 with a Combination of Anti-idiotype Vaccine and CTL Peptides of Carcinoembryonic Antigen
Cancer Res., March 15, 2007; 67(6): 2881 - 2892.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
T. Bachleitner-Hofmann, M. Strohschneider, P. Krieger, M. Sachet, P. Dubsky, H. Hayden, S. F. Schoppmann, R. Pfragner, M. Gnant, J. Friedl, et al.
Heat Shock Treatment of Tumor Lysate-Pulsed Dendritic Cells Enhances Their Capacity to Elicit Antitumor T Cell Responses against Medullary Thyroid Carcinoma
J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4571 - 4577.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dai, S.
Right arrow Articles by Cao, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dai, S.
Right arrow Articles by Cao, X.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online